What Is BBH? VanEck Biotech ETF

BBH is the VanEck Biotech ETF, a concentrated fund that owns the 25 largest US-listed biotechnology companies. It tracks the MarketVector US Listed Biotech 25 Index and weights holdings by market capitalization, which pushes established giants to the top. The expense ratio is 0.35%, low for a sector fund.

Launched in December 2011, BBH is one of the older biotech ETFs on the market. It targets investors who want exposure to the profitable, large-cap end of biotech rather than the speculative small-cap names that dominate equal-weight competitors.

Approximate weights as of mid-2026; refresh quarterly from VanEck's fund page. Each ticker links to its individual stock guide in Walnut.

BBH holds roughly 25 stocks, and its cap-weighted design concentrates the fund heavily. Amgen and Gilead Sciences alone can each exceed 10% of assets, with Vertex, Regeneron, argenx, Alnylam, and Biogen filling out the top ranks. The top 10 positions typically account for around two-thirds of the fund.

The lineup blends large-cap drug developers with a few mid-cap innovators and the healthcare services firm IQVIA. Because so much weight sits in a handful of names, the fortunes of the biggest holdings drive much of BBH's day-to-day movement.

The three main biotech ETFs take different approaches. BBH holds only 25 cap-weighted names, making it the most concentrated in established leaders. The iShares Biotechnology ETF (IBB) holds a much broader roster, while the SPDR S&P Biotech ETF (XBI) equal-weights its holdings, tilting toward smaller, more volatile companies.

Investors who want steadier, large-cap biotech often lean toward BBH or IBB, while those seeking higher-beta exposure to small-cap drug developers prefer XBI. BBH's 0.35% fee undercuts IBB's, though its narrow holdings carry more single-stock risk.

BBH's returns hinge on the large-cap biotech leaders it concentrates in, plus broader sector sentiment around drug pricing, patent cliffs, and merger activity. Its large-cap tilt has historically made it less erratic than small-cap-heavy peers, but biotech as a sector remains prone to sharp swings.

The long-term case rests on aging populations, innovation in areas like gene therapy and immunology, and the pricing power of blockbuster drugs. How that plays out depends on clinical outcomes and regulation, which are inherently uncertain. Past performance does not predict future results.

BBH fits investors who want focused exposure to established, large-cap biotech and can accept concentration in a few dominant names. It typically works as a satellite sleeve within a healthcare or growth allocation rather than a diversified core holding.

Walnut is not an investment adviser, and this is not a recommendation to buy or sell BBH. Whether it belongs in your portfolio depends on your goals, risk tolerance, time horizon, and how much sector-specific risk you are comfortable carrying.

BBH trades on the Nasdaq and can be purchased through any major brokerage, including Robinhood, Fidelity, Schwab, and Public, most of which support fractional shares. Buy it with a market or limit order just as you would an individual stock.

You can also connect your existing broker to Walnut to track BBH within a healthcare or thematic basket, watch how its weight drifts against your targets, and view it alongside the rest of your holdings.

BBH offers cheap, focused exposure to large-cap biotech at 0.35%, but with only about 25 holdings and heavy concentration in a handful of names, it is more of a satellite than a diversified core. It fits investors who want established biotech leaders over the small-cap volatility of equal-weight peers.

Whether BBH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is BBH a buy?

BBH yields ~0.5% as of mid-2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see BBH dividend: yield and schedule.